Categories: News

Harrow Health to Announce Fourth Quarter and Year-End 2020 Financial Results on March 8, 2021

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

NASHVILLE, Tenn., Feb. 25, 2021 (GLOBE NEWSWIRE) — Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2020, on Monday, March 8, 2021, after the Nasdaq market close. The Company will also post its fourth quarter Letter to Shareholders to the “Investors” section of its website, harrowinc.com. Harrow Health will host a conference call and live webcast at 4:45 p.m. Eastern time to discuss the results and provide a business update.

Conference Call Details:  
Date: Monday, March 8, 2021
Time: 4:45 p.m. Eastern time
Participant Dial-in: (888) 506-0062 (U.S.)
(973) 528-0011 (International)
Replay Dial-in (Passcode 39840):
(telephonic replay through April 8, 2021)
(877) 481-4010 (U.S.)
(919) 882-2331 (International)
Webcast:
(online replay through June 8, 2021)
harrowinc.com

About Harrow Health
Harrow Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company. The Company owns ImprimisRx, the nation’s leading ophthalmology outsourcing and pharmaceutical compounding business, which was founded in 2014. Harrow Health also holds large equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries. Harrow Health also owns royalty rights in four clinical-stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please visit the Investors section of the corporate website, harrowinc.com.

Contact:
Jamie Webb, Director of Communications and Investor Relations
jwebb@harrowinc.com
615-733-4737

 

Staff

Recent Posts

Beyond Medical Technologies Announces Filing of Application for Management Cease Trade Order

Vancouver, British Columbia--(Newsfile Corp. - April 16, 2025) - Beyond Medical Technologies Inc. (CSE: DOCT)…

1 hour ago

Insights From Digital Silk’s Recent Study Reveal Key Branding Priorities for U.S. Healthcare Providers

MIAMI, April 16, 2025 /PRNewswire/ -- Digital Silk, an award-winning agency focused on creating brand…

3 hours ago

Terumo Blood and Cell Technologies Names Patrick Daly as Chief Business Officer

Daly, a 30-year veteran of the healthcare industry, is the latest leadership addition to help…

3 hours ago

Cloudforce Launches nebulaONE® on Microsoft Azure: The Leading AI Gateway for Higher Education

NATIONAL HARBOR, Md., April 16, 2025 /PRNewswire/ -- Cloudforce, a Maryland-based leader in cloud and…

3 hours ago

Terumo Health Outcomes Now Offers FDA-Cleared Medis QFR® 3.0 Software for Coronary Physiology Assessment in the US

 – Innovative AI software supports hospital adoption of advanced tools to improve cath lab workflow and…

3 hours ago

THINK Surgical Announces First Use of Maxx Orthopedics’ Freedom® Total Knee implant with the TMINI® Miniature Robotic System

FREMONT, Calif., April 16, 2025 /PRNewswire/ -- THINK Surgical, Inc., an innovator in the field…

3 hours ago